Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
1721-1740 of 2,120 trials

Ovarian Cancer: NIraparib and Dostarlimab Study

We are testing a new treatment combination for patients with recurrent ovarian cancer who cannot have platinum therapy. The study aims to see if this combination helps patients live longer compared to standard chemotherapy.

Recurrent Ovarian CancerConfirmation phase (III)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Atherosclerotic Cardiovascular Disease: Maridebart Cafraglutide

We are studying whether maridebart cafraglutide can improve heart health in people with atherosclerotic cardiovascular disease who are overweight or obese. This trial compares its effects to a placebo alongside standard care.

Arteriosclerotic Cardiovascular DiseaseConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine

Maridebart Cafraglutide for Heart Failure and Obesity

We are studying whether maridebart cafraglutide can improve heart failure symptoms and reduce hospital visits for people with heart failure and obesity. This trial compares the new treatment to a placebo alongside standard care.

Heart FailureConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Melanoma Treatment: Vemurafenib, Cobimetinib, and Atezolizumab

We are studying a combination of three medications for patients with high-risk melanoma to see if it helps achieve a complete response. We also want to understand its effects on survival and safety.

High-Risk MelanomaEfficacy phase (II)No PlaceboStandard MedicinesDermatologyOncology

Bronchopulmonary Dysplasia: Stem Cell Treatment for Preterm Infants

We are studying the safety of umbilical cord stem cells in preterm babies with bronchopulmonary dysplasia. This research aims to see if the treatment can help improve their lung health and overall development.

Bronchopulmonary Dysplasia>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesPediatricsPulmonology

Granulomatosis with Polyangiitis: New Salvage Therapies

We are testing different treatment combinations for patients who haven't responded to standard care for granulomatosis with polyangiitis. The goal is to find the most effective way to help induce remission and improve overall health.

Granulomatosis with Polyangiitis (GPA)1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineRheumatology

Eosinophilic Esophagitis: EP 104GI Treatment Study

We are testing a new treatment called EP 104GI for adults with eosinophilic esophagitis. The study aims to evaluate its safety and effectiveness in reducing symptoms and improving esophageal health.

Eosinophilic Esophagitis1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesAllergologyGastroenterology

Rheumatoid Arthritis: Targeted Therapy vs. Triple Therapy

We are studying whether targeted therapies are more effective than a combination of three other medications for patients with rheumatoid arthritis who haven't responded to standard treatments. The trial also looks at safety and quality of life.

Rheumatoid ArthritisConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineRheumatology

Imlifidase for Severe ANCA-associated Vasculitis

We are studying whether imlifidase, combined with standard care, can improve outcomes for patients with severe ANCA-associated vasculitis and pulmonary hemorrhage. The trial will also assess its safety and effects on health markers.

ANCA-Associated Vasculitis3-6 monthsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesPulmonologyRheumatology

MMRd Uterine Cancer: Pembrolizumab Treatment Study

We are investigating whether pembrolizumab can effectively treat MMRd uterine cancer before surgery. The study will assess how well it works and its safety for patients.

Endometrial Cancer1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementGynecology and ObstetricsOncology

Hepatocellular Carcinoma: NMS-01940153E and Atezolizumab Study

We are studying a new treatment combination for adults with unresectable hepatocellular carcinoma who have been treated with other anti-cancer medicines. The goal is to see how well this combination works and its safety compared to existing options.

Unresectable Hepatocellular CarcinomaEfficacy phase (II)No PlaceboInvestigational MedicinesHepatologyOncology

Hemophilia A: Innovative Treatment Approaches for Patients with Inhibitors

We are exploring various treatment methods for individuals with Hemophilia A who have inhibitors. The goal is to see how well these treatments reduce bleeding and improve health outcomes.

Hemophilia A>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesHematology

Cutaneous Lupus Erythematosus: IMVT-1402 Study

We are evaluating a new treatment for people with active cutaneous lupus erythematosus to see if it improves skin symptoms compared to a placebo. This study aims to assess its safety and effectiveness.

Skin Lupus1-2 yearsEfficacy phase (II)Investigational MedicinesCost ReimbursementDermatologyRheumatology

Multiple Myeloma: [68Ga]Ga-PentixaFor Imaging Study

We are exploring a new imaging method to see how well it detects multiple myeloma lesions in patients at diagnosis or relapse. This study may help improve the way we monitor and treat this condition.

Multiple Myeloma1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Setmelanotide for ROHHAD Syndrome

We are studying the effects of setmelanotide on hypothalamic function and related symptoms in patients with ROHHAD syndrome. This trial aims to understand how the treatment may improve various health aspects over time.

ROHHAD Syndrome1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteEndocrinologyInternal Medicine

Head and Neck Cancer: Niraparib and Dostarlimab Study

We are studying the effects of Niraparib and Dostarlimab combined with chemotherapy and radiotherapy in patients with locally advanced head and neck cancer. The goal is to see if this combination improves treatment outcomes compared to standard approaches.

Squamous Cell Carcinoma of the Head and Neck>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncologyOtolaryngology

Preventing Infections in ICU Patients with Interferon Gamma

We are studying whether interferon gamma can help prevent secondary infections in ICU patients with weakened immune systems. This research may improve recovery and reduce hospital stays.

Sustained Immunosuppression>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteInfectious DiseasesInternal MedicinePulmonology

Stage IV NSCLC: Osimertinib with Chemotherapy

We are studying the combination of osimertinib and chemotherapy for patients with stage IV non-small cell lung cancer who have atypical EGFR mutations. The goal is to evaluate its effectiveness, safety, and impact on quality of life.

Stage IV Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesOncologyPulmonology

Metastatic Non-Small Cell Lung Cancer: Visugromab Treatment

We are studying whether visugromab, combined with standard chemotherapy, can improve outcomes for patients with metastatic non-squamous non-small cell lung cancer. The trial also looks at safety and quality of life during treatment.

Metastatic Non-Squamous Non-Small Cell Lung CancerEfficacy phase (II)Investigational MedicinesPartially RemoteOncology

Metastatic Non-Squamous Non-Small Cell Lung Cancer: Visugromab and Nivolumab Study

We are investigating whether a new treatment combining visugromab and nivolumab with or without docetaxel can improve outcomes for patients with metastatic non-squamous non-small cell lung cancer. This study will help us understand its effectiveness and safety compared to standard treatments.

Metastatic Non-Squamous Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)Investigational MedicinesPartially RemoteOncology